12 patients won't be enough to approve MPL for global use but it should be enough to gain the orphan drug designation.
If companies have less than 2 quarters of funding they just need to answer a few extra questions in their quarterly report. I've held a few companies that have done this without consequence.
- Forums
- ASX - By Stock
- The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
12 patients won't be enough to approve MPL for global use but it...
-
- There are more pages in this discussion • 50 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
|
|||||
Last
17.5¢ |
Change
0.005(2.94%) |
Mkt cap ! $85.12M |
Open | High | Low | Value | Volume |
17.5¢ | 18.0¢ | 17.0¢ | $83.08K | 474.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
12 | 376717 | 17.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
17.5¢ | 144077 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
12 | 376717 | 0.170 |
7 | 256513 | 0.165 |
8 | 396304 | 0.160 |
6 | 336734 | 0.155 |
9 | 229993 | 0.150 |
Price($) | Vol. | No. |
---|---|---|
0.175 | 177741 | 2 |
0.180 | 171989 | 2 |
0.185 | 242471 | 4 |
0.190 | 880847 | 8 |
0.195 | 575777 | 10 |
Last trade - 15.41pm 10/09/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |